Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia Jun 02, 2015 2:00pm EDT
Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 May 05, 2015 4:15pm EDT
Aptose Biosciences Announces Appointment of Dr. Michael Andreeff to Scientific Advisory Board Mar 23, 2015 8:30am EDT
Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference Mar 23, 2015 8:00am EDT
Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 Mar 03, 2015 4:30pm EST
Aptose Biosciences To Host Quarter and Seven Month Transition Period Ended December 31, 2014 Conference Call and Webcast Feb 26, 2015 8:00am EST
Aptose Biosciences to Present at the Cowen & Company 35th Annual Healthcare Conference Feb 25, 2015 4:39pm EST
Aptose Biosciences to Present at the RBC Capital Markets 2015 Global Healthcare Conference Feb 19, 2015 8:00am EST
